

Novel Oral Therapeutic Candidate for the Treatment of Chronic Urticaria

Samjin Pharm. Co., Ltd.

SAMJIN 삼진제약

IMMUNOLOGY	Preclinical
Product Type	Small molecules
Indication	Chronic Urticaria (CU)
Target	Undisclosed GPCR target involved in mast cell activation and degranulation
MoA(Mechanism of Action)	Selective inhibition of a mast cell-associated receptor to suppress degranulation and downstream inflammatory pathways
Competitiveness	<p>This oral small molecule candidate demonstrates strong therapeutic potential with the following attributes:</p> <ul style="list-style-type: none"> • High potency across key mast cell assays under multiple stimulation conditions • Excellent skin distribution and minimal CNS exposure • No hERG inhibition or cardiotoxicity observed • Balanced ADME and favorable PK profile, enabling oral, once-daily dosing → Represents a promising best-in-class oral therapeutic candidate for CU
Development Stage	Preclinical
Route of Administration	Oral (PO), Once daily

Any unauthorized distribution or reproduction of this material is strictly prohibited.